February 8, 2018

The Texas Drug Utilization Review Board held their quarterly meeting on Jan. 26, 2018, to make recommendations about clinical prior authorizations and drugs to be included on the Texas Medicaid Preferred Drug List (PDL).  Available are:

  • A recording of this meeting’s webcast
  • Approved minutes of the Nov. 3, 2017, meeting
  • A report of this quarter’s clinical prior authorization and PDL recommendations
  • The PDL drug class review schedule for April.

Clinical Prior Authorizations


  • HHS will notify providers and stakeholders once an implementation date has been set for Medicaid fee-for-service.
  • Medicaid managed care organizations (MCO) have the option to implement any board-approved clinical prior authorization at any time.

Preferred Drug List

Preferred drugs are medications recommended by the board for their efficaciousness, clinical significance, safety, and cost effectiveness.  


  • PDL recommendations are pending the final decision of the HHS executive commissioner.  HHS-approved decisions from the January and April 2018 board meetings will be incorporated into the July 2018 PDL update.
  • Prescribing providers must adhere to the Medicaid formulary and PDL.
  • MCOs must adhere to the PDL.

About the Texas DUR Board

Board members meet quarterly in Austin to make recommendations about the Medicaid program, including developing and submitting recommendations for the Texas PDL, and suggesting clinical prior authorizations on outpatient prescription drugs. The schedule of future meetings and instructions on how to testify and submit written material for consideration are also available.